콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

SML1606

Sigma-Aldrich

Oseltamivir phosphate

≥98% (HPLC)

동의어(들):

GS4104, (3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate salt

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C16H28N2O4 ·H3PO4
CAS Number:
Molecular Weight:
410.40
MDL number:
UNSPSC 코드:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

분석

≥98% (HPLC)

형태

powder

광학 활성

[α]/D -26 to -36°, c = 1 in H2O

색상

white to beige

solubility

H2O: 30 mg/mL, clear

저장 온도

−20°C

SMILES string

OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1

InChI

1S/C16H28N2O4.H3O4P/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19;1-5(2,3)4/h9,12-15H,5-8,17H2,1-4H3,(H,18,19);(H3,1,2,3,4)/t13-,14+,15+;/m0./s1

InChI key

PGZUMBJQJWIWGJ-ONAKXNSWSA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

관련 카테고리

생화학적/생리학적 작용

Oseltamivir phosphate is an influenza viral neuraminidase inhibitor. Oseltamivir phosphate, an antiviral, is used clinically to treat influenza A and influenza B, and to prevent flu after exposure. Oseltamivir phosphate is hydrolyzed in the liver to its active form, oseltamivir carboxylate, which is an inhibitor of influenza viral neuraminidases essential for viral replication. Oseltamivir has a broad spectrum of activity against a range of influenza A and B subtypes with IC50 values for neuraminidases measured from less than 1 nM to approximately 30 nM, depending on the virus subtype.

픽토그램

Exclamation mark

신호어

Warning

유해 및 위험 성명서

Hazard Classifications

Aquatic Chronic 3 - Eye Irrit. 2 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Mohamed A Kamal et al.
Antimicrobial agents and chemotherapy, 59(9), 5388-5395 (2015-06-24)
A population drug-disease model was developed to describe the time course of influenza virus with and without oseltamivir treatment and to investigate opportunities for antiviral combination therapy. Data included viral titers from 208 subjects, across 4 studies, receiving placebo and
C Joaquín Cáceres et al.
Emerging microbes & infections, 10(1), 1832-1848 (2021-08-25)
Seasonal influenza A virus (IAV) infections are among the most important global health problems. FDA-approved antiviral therapies against IAV include neuraminidase inhibitors, M2 inhibitors, and polymerase inhibitor baloxavir. Resistance against adamantanes (amantadine and rimantadine) is widespread as virtually all IAV
R H Beigi et al.
Clinical pharmacology and therapeutics, 98(4), 403-405 (2015-06-26)
Pregnancy heightens the risk of adverse outcomes from influenza infections. This is true for both seasonal epidemics as well as occasional pandemics. Seasonal influenza vaccines are the focus of disease prevention and are recommended for all pregnant women in any
Shivraj Hariram Nile et al.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 135, 110985-110985 (2019-11-26)
Investigation of antiviral and cytotoxic effect of quercetin 3-glucoside (Q3G) from Dianthus superbus L over influenza virus infection and replication were studied. Moreover, anti-influenza mechanism was screened by time-dependent antiviral assay, virus-induced symptoms and related gene expressions. The blockade of
Brian E Davies
The Journal of antimicrobial chemotherapy, 65 Suppl 2, ii5-ii10 (2010-03-20)
Influenza is a transmissible viral pathogen that continues to cause substantial morbidity and mortality. Oseltamivir is an orally administered antiviral medication that selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication. Treatment of infected children > or

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.